The data from TCGA indicated that the group of STAD patients with higher CXCL2 level had a better overall survival (P = .00086, hazard ratio [HR] = 0.75, Fig. 3A) compared with patients with low CXCL2 level. The gene discussed is CXCL2; the disease is gastric adenocarcinoma.